PL3083616T3 - Bicykliczne związki heterocykliczne i ich zastosowania w terapii - Google Patents
Bicykliczne związki heterocykliczne i ich zastosowania w terapiiInfo
- Publication number
- PL3083616T3 PL3083616T3 PL14815838T PL14815838T PL3083616T3 PL 3083616 T3 PL3083616 T3 PL 3083616T3 PL 14815838 T PL14815838 T PL 14815838T PL 14815838 T PL14815838 T PL 14815838T PL 3083616 T3 PL3083616 T3 PL 3083616T3
- Authority
- PL
- Poland
- Prior art keywords
- therapy
- bicyclic heterocycle
- heterocycle compounds
- compounds
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322755.8A GB201322755D0 (en) | 2013-12-20 | 2013-12-20 | Bicyclic heterocycle compounds and their uses in therapy |
| GB201406986A GB201406986D0 (en) | 2014-04-17 | 2014-04-17 | Bicyclic heterocycle compounds and their uses in therapy |
| EP14815838.9A EP3083616B1 (en) | 2013-12-20 | 2014-12-19 | Bicyclic heterocycle compounds and their uses in therapy |
| PCT/GB2014/053778 WO2015092420A1 (en) | 2013-12-20 | 2014-12-19 | Bicyclic heterocycle compounds and their uses in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3083616T3 true PL3083616T3 (pl) | 2021-12-06 |
Family
ID=52134239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14815838T PL3083616T3 (pl) | 2013-12-20 | 2014-12-19 | Bicykliczne związki heterocykliczne i ich zastosowania w terapii |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9783538B2 (enExample) |
| EP (2) | EP3686200A3 (enExample) |
| JP (3) | JP6470756B2 (enExample) |
| KR (1) | KR102408262B1 (enExample) |
| CN (3) | CN105829310B (enExample) |
| AU (2) | AU2014369446C1 (enExample) |
| BR (2) | BR112016014561B1 (enExample) |
| CA (1) | CA2933939C (enExample) |
| CY (1) | CY1124436T1 (enExample) |
| DK (1) | DK3083616T3 (enExample) |
| ES (1) | ES2883289T3 (enExample) |
| HR (1) | HRP20211406T1 (enExample) |
| HU (1) | HUE056297T2 (enExample) |
| IL (1) | IL246239B (enExample) |
| LT (1) | LT3083616T (enExample) |
| MX (1) | MX380469B (enExample) |
| MY (2) | MY193649A (enExample) |
| NZ (2) | NZ758528A (enExample) |
| PH (1) | PH12016501139B1 (enExample) |
| PL (1) | PL3083616T3 (enExample) |
| PT (1) | PT3083616T (enExample) |
| RS (1) | RS62301B1 (enExample) |
| RU (1) | RU2696310C1 (enExample) |
| SA (1) | SA516371360B1 (enExample) |
| SG (2) | SG10201808102WA (enExample) |
| SI (1) | SI3083616T1 (enExample) |
| SM (1) | SMT202100497T1 (enExample) |
| TW (1) | TWI649319B (enExample) |
| WO (1) | WO2015092420A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| SG10201808102WA (en) * | 2013-12-20 | 2018-10-30 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10940127B2 (en) | 2015-11-25 | 2021-03-09 | Io Therapeutics, Inc. | Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer |
| AU2017223233A1 (en) * | 2016-02-24 | 2018-08-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| JP2019514878A (ja) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｉｐｋ２阻害剤を含むコンジュゲート |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP2019517557A (ja) | 2016-06-10 | 2019-06-24 | アイオー セラピューティクス インコーポレイテッド | 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子 |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| AU2018301810A1 (en) | 2017-07-13 | 2020-01-23 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| US10363272B2 (en) | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| CA3130706A1 (en) | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| WO2021058794A1 (en) | 2019-09-25 | 2021-04-01 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| US20230348352A1 (en) * | 2020-05-04 | 2023-11-02 | Otsuka Pharmaceutical Co., Ltd. | Methods for synthesizing anhydrous lactic acid |
| JP7690493B2 (ja) * | 2020-05-04 | 2025-06-10 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法 |
| IL298645A (en) | 2020-06-04 | 2023-01-01 | Beigene Ltd | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazines as iap antagonists |
| MX2023001730A (es) * | 2020-08-12 | 2023-05-18 | Archer Daniels Midland Co | Purificacion del ester dimetilico del acido 2,5-furandicarboxilico y otros productos esterificados. |
| US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| KR20230069144A (ko) * | 2020-09-14 | 2023-05-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태 |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CA3229750A1 (en) | 2021-08-20 | 2023-02-23 | Otsuka Pharmaceutical Co., Ltd. | Combination drug |
| CA3234317A1 (en) | 2021-10-22 | 2023-12-14 | Wa Xian | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| US20250032464A1 (en) * | 2021-11-05 | 2025-01-30 | Haihe Biopharma Co., Ltd. | Solid dispersion, preparation method therefor, and solid formulation containing same |
| EP4486352A1 (en) | 2022-03-04 | 2025-01-08 | Otsuka Pharmaceutical Co., Ltd. | Methods of treating cancer with iap antagonist compounds and combination therapies |
| WO2023230432A1 (en) | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
| AU2022476674A1 (en) | 2022-08-31 | 2025-04-17 | Taiho Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| CN116375700B (zh) * | 2023-01-10 | 2024-12-17 | 中国科学院成都生物研究所 | 一种4-氮杂吲哚啉类化合物及其合成方法与应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2025029809A1 (en) | 2023-07-31 | 2025-02-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compositions including tolinapant and packaging |
| WO2025235719A1 (en) * | 2024-05-08 | 2025-11-13 | Viiv Healthcare Company | Dimeric smac mimetics useful in hiv therapy |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080330A (en) * | 1975-06-23 | 1978-03-21 | Delmar Chemicals Limited | Phenylindolines and process for their production |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| TW218875B (enExample) | 1992-03-09 | 1994-01-11 | Takeda Pharm Industry Co Ltd | |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| ES2200039T3 (es) | 1995-12-08 | 2004-03-01 | Pfizer Inc. | Derivados heterociclicos sustituidos como antagonistas de crf. |
| EP0892780B1 (en) | 1996-02-22 | 2002-11-20 | Bristol-Myers Squibb Pharma Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| CA2257950A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| AU732863B2 (en) | 1997-04-18 | 2001-05-03 | Smithkline Beecham Plc | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity |
| HUP0100926A3 (en) | 1998-02-26 | 2003-03-28 | Neurogen Corp Branford | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
| US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| CN1303376A (zh) | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| CN1323295A (zh) | 1998-08-26 | 2001-11-21 | 阿文蒂斯药物有限公司 | 调节细胞粘着抑制作用的氮杂双环化合物 |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU3555200A (en) | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
| GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
| AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| WO2001017942A1 (en) | 1999-09-04 | 2001-03-15 | Astrazeneca Ab | Amides as inhibitors for pyruvate dehydrogenase |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| CA2433090A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| WO2002080853A2 (en) | 2001-04-09 | 2002-10-17 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| WO2003090748A1 (fr) | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Compay Limited. | Utilisation de composes a antagonisme anti-ccr |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| WO2004078715A1 (ja) | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | ２，６－ジ置換スチリルを有する含窒素へテロ環誘導体 |
| GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| AU2004266233A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| NZ588799A (en) | 2004-07-02 | 2012-06-29 | Genentech Inc | Inhibitors of iap |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| WO2006032987A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Indoline compounds and their use in the treatment of arteriosclerosis |
| DK1836201T4 (da) | 2004-12-20 | 2013-11-11 | Genentech Inc | Pyrrolidininhibitorer af IAP. |
| PL1851200T3 (pl) | 2005-02-25 | 2014-06-30 | Tetralogic Pharm Corp | Dimeryczne inhibitory IAP |
| AU2006311101A1 (en) | 2005-11-11 | 2007-05-18 | F. Hoffmann-La Roche Ag | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa |
| CA2632807A1 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| WO2007073405A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| FR2896504B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| GB0602335D0 (en) | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| EP2029592A1 (en) | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2049524A2 (en) | 2006-07-24 | 2009-04-22 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
| RU2009117701A (ru) | 2006-10-12 | 2010-11-20 | Новартис АГ (CH) | Производные пирролидина в качестве ингибиторов iap |
| US8048886B2 (en) | 2006-12-07 | 2011-11-01 | Novartis Ag | Substituted pyrazine-3-one-derivatives as IAP inhibitors |
| CA2680173A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| ES2424977T3 (es) | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| WO2009067233A1 (en) | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
| BRPI0906785A2 (pt) | 2008-01-24 | 2015-07-14 | Tetralogic Pharm Corp | Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune |
| WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| GB0810902D0 (en) * | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| CN102427731B (zh) | 2009-02-27 | 2015-05-13 | 英安塔制药有限公司 | 丙型肝炎病毒抑制剂 |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| WO2010129467A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| WO2010138666A1 (en) | 2009-05-28 | 2010-12-02 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
| UY33794A (es) * | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| EP2763531A4 (en) | 2011-10-03 | 2015-11-18 | Univ Columbia | NEW MOLECULES FOR THE SELECTIVE INHIBITION OF HISTONDEACETYLASE 6 IN RELATION TO HISTONDEACETYLASE 1 |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| SG10201808102WA (en) * | 2013-12-20 | 2018-10-30 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| WO2015106025A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| US20230348352A1 (en) | 2020-05-04 | 2023-11-02 | Otsuka Pharmaceutical Co., Ltd. | Methods for synthesizing anhydrous lactic acid |
| JP7690493B2 (ja) | 2020-05-04 | 2025-06-10 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法 |
| EP4486352A1 (en) | 2022-03-04 | 2025-01-08 | Otsuka Pharmaceutical Co., Ltd. | Methods of treating cancer with iap antagonist compounds and combination therapies |
| AU2022476674A1 (en) | 2022-08-31 | 2025-04-17 | Taiho Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
-
2014
- 2014-12-19 SG SG10201808102WA patent/SG10201808102WA/en unknown
- 2014-12-19 AU AU2014369446A patent/AU2014369446C1/en active Active
- 2014-12-19 LT LTEPPCT/GB2014/053778T patent/LT3083616T/lt unknown
- 2014-12-19 JP JP2016541373A patent/JP6470756B2/ja active Active
- 2014-12-19 MX MX2016008131A patent/MX380469B/es unknown
- 2014-12-19 PT PT148158389T patent/PT3083616T/pt unknown
- 2014-12-19 SI SI201431877T patent/SI3083616T1/sl unknown
- 2014-12-19 DK DK14815838.9T patent/DK3083616T3/da active
- 2014-12-19 MY MYPI2020002540A patent/MY193649A/en unknown
- 2014-12-19 BR BR112016014561-5A patent/BR112016014561B1/pt active IP Right Grant
- 2014-12-19 HR HRP20211406TT patent/HRP20211406T1/hr unknown
- 2014-12-19 CN CN201480069940.4A patent/CN105829310B/zh active Active
- 2014-12-19 CA CA2933939A patent/CA2933939C/en active Active
- 2014-12-19 US US15/105,360 patent/US9783538B2/en active Active
- 2014-12-19 CN CN201811129977.8A patent/CN109336883B/zh active Active
- 2014-12-19 HU HUE14815838A patent/HUE056297T2/hu unknown
- 2014-12-19 ES ES14815838T patent/ES2883289T3/es active Active
- 2014-12-19 EP EP19219371.2A patent/EP3686200A3/en active Pending
- 2014-12-19 TW TW103144450A patent/TWI649319B/zh active
- 2014-12-19 KR KR1020167019182A patent/KR102408262B1/ko active Active
- 2014-12-19 NZ NZ758528A patent/NZ758528A/en unknown
- 2014-12-19 SG SG11201604795RA patent/SG11201604795RA/en unknown
- 2014-12-19 PL PL14815838T patent/PL3083616T3/pl unknown
- 2014-12-19 MY MYPI2016701668A patent/MY186311A/en unknown
- 2014-12-19 CN CN202210613741.1A patent/CN115368356B/zh active Active
- 2014-12-19 SM SM20210497T patent/SMT202100497T1/it unknown
- 2014-12-19 NZ NZ71990514A patent/NZ719905A/en unknown
- 2014-12-19 BR BR122022015241-4A patent/BR122022015241B1/pt active IP Right Grant
- 2014-12-19 RS RS20211096A patent/RS62301B1/sr unknown
- 2014-12-19 WO PCT/GB2014/053778 patent/WO2015092420A1/en not_active Ceased
- 2014-12-19 RU RU2016129472A patent/RU2696310C1/ru active
- 2014-12-19 EP EP14815838.9A patent/EP3083616B1/en active Active
-
2016
- 2016-06-13 PH PH12016501139A patent/PH12016501139B1/en unknown
- 2016-06-15 IL IL246239A patent/IL246239B/en active IP Right Grant
- 2016-06-19 SA SA516371360A patent/SA516371360B1/ar unknown
-
2017
- 2017-08-11 US US15/675,052 patent/US10618895B2/en active Active
-
2019
- 2019-01-17 JP JP2019005876A patent/JP6735369B2/ja active Active
- 2019-02-07 AU AU2019200840A patent/AU2019200840C1/en active Active
-
2020
- 2020-02-19 US US16/795,117 patent/US11225476B2/en active Active
- 2020-07-10 JP JP2020119260A patent/JP7110279B2/ja active Active
-
2021
- 2021-08-12 CY CY20211100729T patent/CY1124436T1/el unknown
- 2021-12-07 US US17/643,083 patent/US11643410B2/en active Active
-
2022
- 2022-12-21 US US18/069,571 patent/US12202828B2/en active Active
-
2024
- 2024-12-09 US US18/973,574 patent/US20250296930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246239B (en) | Bicyclic heterocyclic compounds and their uses in healing | |
| GB201218862D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| GB201218850D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201218864D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PL2951177T3 (pl) | Związki imidazopirydynowe i ich zastosowania | |
| ZA201307797B (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| SG11201602579SA (en) | Bicyclic alkyne derivatives and uses thereof | |
| GB2515865B (en) | Use of galactooligosaccharides in therapy | |
| ZA201607581B (en) | Dosage forms and therapeutic uses l-4lchlorokynurenine | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| GB201304038D0 (en) | Treated cells and therapeutic uses | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| HUE036306T2 (hu) | Odiparcil alkalmazása mukopoliszacharidózis kezelésében | |
| GB201322755D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| HK1230598A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201406986D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis |